The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Subcutaneous formulation of Tecentriq demonstrates positive phase III results

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq (atezolizumab) showed non-inferior levels of Tecentriq in the blood, when injected subcutaneously, compared with intravenous infusion.

Tecentriq is sponsored by Genentech. 

The study included cancer immunotherapy-naïve patients with locally advanced or metastatic NSCLC for whom prior platinum therapy has failed. 

The safety profile of the subcutaneous formulation was consistent with that of IV Tecentriq.

Subcutaneous administration would reduce the time patients spend receiving treatment from 30-60 minutes with IV infusion to only 3-8 minutes. 

Genentech will share detailed findings of the IMscin001 study at an upcoming medical meeting and submit them for regulatory approval to health authorities globally, including FDA and European Medicines Agency.

Table of Contents

YOU MAY BE INTERESTED IN

In Brief

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer. 
Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.
Clinical Roundup

Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows

Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account